Home | About us | Editorial Board | Search | Ahead of print | Current Issue | Archives | Instructions | Online submissionContact Us   |  Subscribe   |  Advertise   |  Login  Page layout
Wide layoutNarrow layoutFull screen layout
Lung India Official publication of Indian Chest Society  
  Users Online: 755   Home Print this page  Email this page Small font size Default font size Increase font size
Year : 2021  |  Volume : 38  |  Issue : 7  |  Page : 53-57

Coagulopathy in COVID-19

1 Medical student, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 Division of Thoracic Medicine and Surgery, Temple University Hospital, Philadelphia, Pennsylvania, USA

Correspondence Address:
Dr. Parth Rali
Division of Thoracic Medicine and Surgery, Temple University Hospital, Philadelphia, Pennsylvania
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/lungindia.lungindia_226_20

Rights and Permissions

Hemostatic derangement is a hallmark in severe COVID-19. Markedly elevation of D-dimer and fibrinogen degradation product levels were observed in patients with severe COVID-19 higher and 71.4% of nonsurvivors met the International Society of Thrombosis and Haemostasis criteria of disseminated intravascular coagulation (DIC). Although the clinical and epidemiological features of COVID-19 have been well-described, the underlying mechanism influencing disease severity remains to be elucidated. Herein, the aim of this review article is to evaluate hemostasis in the pathogenesis of COVID-19 and its role in the management of this unprecedented pandemic.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded195    
    Comments [Add]    

Recommend this journal